RecruitingPhase 1NCT07329621

A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults

A Phase 1, Open-label, Positron Emission Tomography (PET) Trial to Measure Serotonin 5-HT2A Receptor Occupancy Following Single Oral Doses of MSP-2020 in Healthy Male Adults


Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Enrollment

18 participants

Start Date

Jan 15, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study is to see how well MSP-2020 attaches to specific targets in the brain called serotonin type 2A receptors (5-HT2AR). This study will also look at how much of the study drug (and its metabolite) is in the blood and how long the study drug stays in the blood, as well as the safety of MSP 2020.


Eligibility

Sex: MALEMin Age: 23 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This is a brain imaging study testing a new radioactive tracer called MSP-2020 in healthy adult men to see how well it binds to a specific brain receptor called serotonin 5-HT2A. These types of studies help researchers understand how new drugs or compounds interact with brain chemistry, which is important for developing treatments for mental health conditions. **You may be eligible if...** - You are a healthy adult male - Your BMI is between 18 and 32 - You are in good general health confirmed by medical history, physical exam, ECG, blood tests, and an echocardiogram - You are able to stay at the clinical research unit for up to 4 days **You may NOT be eligible if...** - You have a first-degree relative (parent, sibling) with schizophrenia, psychotic disorder, or bipolar disorder - You have a known allergy to the tracer used in the scan - You have metal implants, a pacemaker, or other conditions that prevent you from having an MRI - You have had prior radiation exposure from research studies - You have claustrophobia or are unable to lie still for the MRI scan Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMSP-2020

capsule


Locations(1)

HMR Hammersmith Medicines Research Ltd.

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07329621